Profile data is unavailable for this security.
About the company
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.
- Revenue in CAD (TTM)348.64m
- Net income in CAD-30.73m
- Incorporated2015
- Employees725.00
- LocationKnight Therapeutics Inc3400 De Maisonneuve Blvd WMONTREAL H3Z 3B8CanadaCAN
- Phone+1 (514) 484-4483
- Fax+1 (514) 481-4116
- Websitehttps://www.gud-knight.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arch Biopartners Inc | 1.38m | -2.57m | 129.30m | -- | -- | -- | -- | 93.45 | -0.0409 | -0.0409 | 0.0221 | -0.1021 | 0.9363 | -- | 1.88 | -- | -174.05 | -214.82 | -- | -- | -- | -- | -185.89 | -180.45 | -- | -3.57 | -- | -- | 105.63 | -- | -136.30 | -- | -- | -- |
| Biosyent Inc | 33.82m | 7.15m | 130.95m | 0.00 | 18.54 | 3.63 | 17.18 | 3.87 | 0.5988 | 0.5988 | 2.83 | 3.06 | 0.8352 | 1.34 | 7.74 | -- | 17.66 | 14.77 | 20.16 | 16.92 | 79.77 | 79.74 | 21.14 | 19.99 | 4.90 | -- | 0.0309 | 9.26 | 13.12 | 7.97 | 18.35 | 2.52 | -2.67 | -- |
| Spectral Medical Inc | 2.01m | -25.08m | 152.72m | 29.00 | -- | -- | -- | 76.13 | -0.0895 | -0.0896 | 0.0072 | -0.1106 | 0.2369 | 3.88 | 3.80 | 69,172.41 | -296.18 | -109.65 | -- | -175.35 | 39.78 | 63.74 | -1,250.20 | -445.72 | 0.2057 | -1.22 | -- | -- | -4.14 | -16.08 | -104.12 | -- | 31.53 | -- |
| Cipher Pharmaceuticals Inc | 37.03m | 22.19m | 325.23m | 9.00 | 14.41 | 2.35 | 12.47 | 8.78 | 0.882 | 0.882 | 1.48 | 5.41 | 0.2166 | 1.30 | 2.66 | 4,114,980.00 | 12.98 | 21.53 | 14.60 | 27.40 | 80.78 | 83.58 | 59.92 | 57.31 | 1.64 | -- | 0.2919 | 0.00 | 2.36 | -1.44 | -23.48 | 76.18 | -53.51 | -- |
| Aurora Cannabis Inc | 296.39m | -29.03m | 349.02m | 1.07k | -- | 0.6424 | -- | 1.18 | -0.6063 | -0.8749 | 5.77 | 9.90 | 0.3643 | 1.69 | 7.42 | 276,222.80 | -3.94 | -- | -4.87 | -- | -0.0165 | -- | -10.81 | -- | 1.88 | -- | 0.1476 | -- | -- | -- | -- | -- | -- | -- |
| Knight Therapeutics Inc | 348.64m | -30.73m | 520.03m | 725.00 | -- | 0.672 | 26.17 | 1.49 | -0.2979 | -0.2979 | 3.42 | 7.66 | 0.3533 | 1.59 | 4.02 | 480,878.60 | -3.11 | 0.3477 | -3.53 | 0.4156 | 48.26 | 46.28 | -8.81 | 1.69 | 2.39 | 0.2385 | 0.07 | 0.00 | 11.80 | 92.24 | 43.68 | -- | 20.79 | -- |
| Canopy Growth Corp | 280.50m | -585.69m | 663.09m | 1.03k | -- | 1.02 | -- | 2.36 | -6.98 | -6.73 | 3.32 | 5.43 | 0.1934 | 2.17 | 6.16 | 272,590.90 | -40.38 | -26.08 | -48.35 | -28.67 | 31.47 | 2.59 | -208.81 | -333.29 | 1.07 | -0.2973 | 0.5462 | -- | -10.83 | 5.59 | 84.29 | -- | -64.60 | -- |
| Cronos Group Inc | 155.68m | -66.57m | 1.16bn | 626.00 | -- | 0.7652 | -- | 7.44 | -0.175 | -0.1745 | 0.4068 | 3.96 | 0.0953 | 2.28 | 6.14 | -- | -4.20 | 6.43 | -4.43 | 7.11 | 14.66 | -10.54 | -44.12 | 147.07 | 23.05 | -- | 0.00 | -- | 0.5672 | 48.40 | 54.99 | -- | -50.99 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Gestion de Portefeuille Strat�gique Medici, Inc.as of 29 Feb 2024 | 12.97m | 12.84% |
| QV Investors, Inc.as of 30 Aug 2024 | 4.75m | 4.70% |
| Dimensional Fund Advisors LPas of 03 Oct 2024 | 2.32m | 2.30% |
| COTE 100, Inc.as of 31 Dec 2023 | 794.00k | 0.79% |
| Fidelity Investments Canada ULCas of 31 Aug 2024 | 420.00k | 0.42% |
| Bessemer Investment Management LLCas of 31 Jul 2024 | 411.03k | 0.41% |
| Artisan Partners LPas of 30 Sep 2024 | 333.95k | 0.33% |
| North Growth Management Ltd.as of 30 Jun 2024 | 327.01k | 0.32% |
| Dimensional Fund Advisors Ltd.as of 03 Oct 2024 | 300.88k | 0.30% |
| CI Investments, Inc.as of 30 Jun 2024 | 252.70k | 0.25% |
